Competition among drugs vying for a leading position in the future advanced renal cell carcinoma market just got a little tougher, with Merck & Co. Inc. releasing more top-line data from the KEYNOTE-426 study showing a combination of its PD-1 inhibitor, Keytruda (pembrolizumab), with Pfizer Inc.'s tyrosine kinase inhibitor, Inlyta (axitinib), improved overall survival, PFS and ORR in the first-line treatment of condition.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?